These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 7727053)

  • 41. Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM).
    Spengler M; Hänsel G; Boehme K
    Horm Metab Res Suppl; 1992; 26():50-1. PubMed ID: 1490692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of acarbose (BAY-g-5421) on expression of noninsulin-dependent diabetes mellitus in sucrose-fed SHR/N-corpulent rats.
    Carswell N; Michaelis OE; Prather ES
    J Nutr; 1989 Mar; 119(3):388-94. PubMed ID: 2646401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modification in sucrose tolerance test with acarbose, guargum and their combination in patients with non-insulin dependent diabetes.
    Shah PK; Lakhotia M; Purohit A; Jain SK; Gupta SK; Bhandari P
    J Assoc Physicians India; 1993 Nov; 41(11):703-5. PubMed ID: 8005921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acarbose: its role in the treatment of diabetes mellitus.
    Campbell LK; White JR; Campbell RK
    Ann Pharmacother; 1996 Nov; 30(11):1255-62. PubMed ID: 8913408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of acarbose on glucose intolerance in patients with non-insulin-dependent diabetes mellitus.
    Noda K; Umeda F; Nawata H
    Diabetes Res Clin Pract; 1997 Aug; 37(2):129-36. PubMed ID: 9279483
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study.
    Spengler M; Cagatay M
    Clin Invest Med; 1995 Aug; 18(4):325-31. PubMed ID: 8549020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative tolerability profiles of oral antidiabetic agents.
    Krentz AJ; Ferner RE; Bailey CJ
    Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [New, in Austria registered specialty drugs. Glucobay (acarbose)].
    Sturm M
    Wien Klin Wochenschr; 1992; 104(11):329-36. PubMed ID: 1621396
    [No Abstract]   [Full Text] [Related]  

  • 49. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Int J Obes Relat Metab Disord; 1997 Sep; 21(9):756-63. PubMed ID: 9376887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
    Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?
    Joubert PH; Venter HL; Foukaridis GN
    Br J Clin Pharmacol; 1990 Sep; 30(3):391-6. PubMed ID: 2223417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acarbose for non-insulin-dependent diabetes mellitus.
    Drug Ther Bull; 1994 Jul; 32(7):51-3. PubMed ID: 7635034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of graded alpha-glucosidase inhibition on sugar absorption in vivo.
    Madariaga H; Lee PC; Heitlinger LA; Lebenthal E
    Dig Dis Sci; 1988 Aug; 33(8):1020-4. PubMed ID: 3292164
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence.
    Scorpiglione N; Belfiglio M; Carinci F; Cavaliere D; De Curtis A; Franciosi M; Mari E; Sacco M; Tognoni G; Nicolucci A
    Eur J Clin Pharmacol; 1999 Jun; 55(4):239-49. PubMed ID: 10424314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
    Reuser AJ; Wisselaar HA
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():19-24. PubMed ID: 8001622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nutritional recommendations for diabetic patients and treatment with alpha-glucosidase inhibitors.
    Toeller M
    Drugs; 1992; 44 Suppl 3():13-20. PubMed ID: 1280573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A review of the safety and efficacy of acarbose in diabetes mellitus.
    Yee HS; Fong NT
    Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.